The Food and Drug Administration (FDA) is expected to follow the recommendation of its advisory panel and to rule in favor of a new eye medicine developed by Regeneron Pharmaceuticals and Bayer AG called Eylea. This ruling is expected on August 20, 2011.
Wet age-related macular degeneration is the most serious form of macular degeneration and affects approximately 1.5 million Americans and is the leading cause of blindness among the elderly. The current drugs available to patients are Avastin and Lucentis. Eylea’s advantage over its competitors is its two-month dosing compared to their monthly dosing.
Clinical trials demonstrated that injections of Eylea every two months was effective as the monthly dosing of the Lucentis and Avastin and that monthly monitoring of patients receiving Eylea was not needed.*